biotech · Melanoma · Previously untreated, unresectable, or metastatic melanoma · IOBTQ
IO Biotech
IO Biotech is a biotech organization headquartered in copenhagen, DK. It trades on NYSE under ticker IOBTQ. Primary therapeutic focus areas include Melanoma, Previously untreated, unresectable, or metastatic melanoma, ad
Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK HQ
2015 Founded
50 Employees
Public company Type
IOBTQ · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ole Maaloesvej 3, Copenhagen, Denmark 2200, DK
- Founded
- 2015
- Employees
- 50
- Programs
- 16
- Drugs
- 8
- Patents
- 21
NRX 194204
Phase 2 · small molecule · Castration Resistant Prostate Cancer
NRX 194204 for Castration Resistant Prostate Cancer is a Phase 2 program (small_molecule) at IO Biotech with 1 ClinicalTrials.gov record(s).
Internal code 4204-202-2011
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- IO Biotech
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Castration Resistant Prostate Cancer
- Status
- completed
- Trials
- 1